Rapid Quantitative Analysis of nalysis of

Rapid Quantitative Analysis of

Analysis by LC-MS/MSfor Clinical ResearchAnalysis of

Immunosuppressant Drugs in Blood and

for Clinical Research

Linda CôtégPlasma Senior Application Specialist

Agilent Technologies

1

For Research Use Only. Notfor use in diagnostic procedures.

Objectives

During Todays webinar, we will be discussing: • A four minute research method for quantifying five immunosuppressive

drugs Cyclosporin A, everolimus, mycophenolic acid, sirolimus and tacrolimus

• A two minute research method for quantifying four immunosuppressive drugs CyclosporinCyclosporin AA, everolimuseverolimus, sirolimussirolimus andand tacrolimustacrolimus

• The use of back-flushing, matrix-stripping liquid chromatography to reduce the throughput of matrix to the mass spectrometer

• The use of the same hardware and reagents for both research methods allowing for the greatest flexibility while eliminating the need to maintain multiple configurations and solvents

• TTypicalypical performancperformancee resultsresults forfor bothboth methodsmethods

• Calibrators, Internal Standards, Controls: which one to use?

• Tips and tricks

2


Compound structures

Cyclosporin A (Cs A) Mycophenolic Acid (MPA) Mycophenolic Acid – Gluc (MPA-G)

Everolimus (Eve) Sirolimus (Sir) Tacrolimus (Tac)

3


Sample preparation

• Mycophenolic acid and its glucoronide are typically measuredin plasma since they are not found in any other blood fractionanalysedanalysed

• However, Cyclosporine A, everolimus, sirolimus andtacrolimus are found distributed throughout blood fractionsgand must be measured in whole blood

4


Sample Preparation – Protein Crash + ZnSO4

100 µL of plasma or whole blood+

200 µL of precipitating reagent (1:4 v/v 0.4M ZnSO4:methanol) containing internal standards

Vortex for 30 seconds

Centrifuge @ 10000 rpm for 4 minutes

Transfer clear supernatant in autosampler vialp p

Analyze by LC-MS/MSy y

5


Configuration for on-line sample cleanupMatrix stripping liquid chromatography which allows for l th h t t th t tcleaner throughput to the mass spectrometer

Position 1

Samples are injected onto a trapping column where the immunosuppressants areimmunosuppressants are retained and washed, reducing throughput of matrix to the mass spectrometer. p

6


Configuration for on-line sample cleanup

Position 1 Position 2

Aft 0 5 i t l i it h d d l t l t d t l ti l l h f th

7

After 0.5 minutes, a valve is switched and analytes are eluted onto an analytical column where further chromatography is performed.


On-line sample cleanup configuration pictures

1: Analytical pump2: Loading pump2: Loading pump3: Column compartement4: Autosampler

3

2

3

4

1

8


On-line sample cleanup configuration pictures

Column compartment:1: Trapping column1: Trapping column2: Analytical column

2 1

Autosampler:Inline filter 0.2 µm

9


What is MRM? (Multiple Reaction Monitoring)

Ions

Spectrum with Q1 lets only Collision cell b k i 210

Q3 monitors only

210

backgroundions (from ESI)

target ion 210 pass through

210

breaks ion 210 apart

characteristic fragment 158 from ion 210 for quantitation

222

268 280165 210158

191

quantitation

158

170 210 250 290 190 210 150 170 190 210 160no chemical background

10


Questions

11


12


Four minute research method for quantifying five immunosuppressive drugs Cyclosporin A, everolirnus, mycophenolic acid, sirolimus and tacrolimus

Four minute research method LC Conditions

Columns: Trapping: Zorbax Eclipse Plus C18, 2.1x12.5mm, 5µmAnalytical: Poroshell 120 EC-C18, 3x50mm, 2.7µm

Columns Temp: 60 °C Injection volume: 40 µL (2 µL for MPA)Needle Wash: 1:1:1:1 MeOH:ACN:IPA:H2O + 0.1% formic acid

10 seconds (60 seconds for MPA)Injector Temp: 4 °C S it hi V l 0 0 i t P iti 1Switching Valve: 0.0 minutes – Position 1

0.5 minutes – Position 22.4 minutes – Position 1

Mobile Phase: A: 10 mM NH4 Acetate + 0.2% Formic Acid in WaterB: 10 mM NH4 Acetate + 0 2% Formic Acid in MethanolB: 10 mM NH4 Acetate + 0.2% Formic Acid in Methanol

Pump Gradients: (followed by 30 seconds post time)

Loading Pump (1260): Analytical Pump (1290):

13


Poroshell 120 Columns for HPLC and UHPLC:

Poroshell 120 is a high efficiency, high resolution column choice for enhancing productivity in LC and LC/MS

• Poroshell 120 Columns have:• 80-90% efficiency of sub 2um• At ~40-50% lower pressure• 2X efficiency of 3.5um (totally porous)• A 2um frit to reduce clogging

0.5um

u t to educe c ogg g• A 600 bar pressure limit for HPLC or

UHPLC use 1.7um

• The superficially porous particle is 2.7um witha solid core (1.7um) and porous outer layerwith a 0 5um diffusion path

0.5um

with a 0.5um diffusion path

14


Poroshell 120 Resists Plugging with 2 um Frit Use with Plasma or Similar MatricesUse with Plasma or Similar Matrices

Column: Poroshell 120 EC-C18, 3.0 x 50mm, 2.7um LC: Agilent 1200 RRLC (SL) Sample: Precipitated Plasma: 2 parts Plasma: 7 Parts 20/80 Water-MeCN w/0.1 % Formic Acid with 1 Part Diflusinalin 50/50 Water-MeCN 10 ug/ml (Final concentration Diflusinal 1 ug/ml) Shaken and allowed to settle 10 minutesNot Centrifuged/ Not Filtered

Diflusinal in Plasma

380

400 200000

Not Centrifuged/ Not FilteredInjection Volume: 1ul injections

Solvent A: Water w/0.1 % TFASolvent B: MeCN w/0.08 % TFAFlow Rate 1 ml/min 1 ul injectionTime % B

260

280

300

320

340

360

140000

160000

180000Time % B0 200.5 900.6 901.1 202.5 20

140

160

180

200

220

240

Pres

sure

80000

100000

120000

Effic

ienc

y (N

)

End PressPlates

0

20

40

60

80

100

120

0

20000

40000

60000 Good lifetime with plasma samples!

01 501 1001 1501 2001 2501

Injections

0

15


QQQ MS/MS Research Method Conditions

Agilent 6460 QQQ MS/MSIon Mode: Agilent Jet Stream (AJS)

El t iti i i tiElectrospray, positive ionization

Ion source conditionsDrying gas temperature: 225°Cy g gas e pe a u e 5 CDrying gas flow: 9 L/minNebulizer pressure: 35 psiSheath gas temperature: 325°CSheath gas flow: 12 L/minSheath gas flow: 12 L/minCapillary voltage: 4000 VNozzle voltage: 300 VQ1/Q3 resolution: 0.7 unit ∆ EMV 200 V (0V for MPA)

Note: During research method development, MPA was evaluated in positive and negativenegative modemode andand foundfound toto performperform betterbetter iinn positivepositive modemode

16


Internal Standards

Analyte Internal StandardCyclosporin A Cyclosporin DEverolimus AscomycinMycophenolic Acid Mycophenolic Acid-d3

Sirolimus AscomycinSirolimus AscomycinTacrolimus Ascomycin

17


MRM Transitions tablePrecursor ions are ammonium adducts (except MPA and MPA-d3)

C d P I P d I D ll F (V) CE(V)Compound Prec Ion Prod Ion Dwell Frag (V) CE (V)Cyclosporine D 1233.9 1216.9 10 175 12Cyclosporine A 1219.9 1202.8 10 170 12Everolimus 975.6 908.5 10 185 12Sirolimus 931.6 864.5 10 170 12Tacrolimus 821.5 768.4 10 170 16Ascomycin 809.5 756.4 10 175 16Mycophenolic Acid Gluc 514.2 207.0 10 95 36Mycophenolic Acid D 3242 2101 10 80 16Mycophenolic Acid D3 324.2 210.1 10 80 16Mycophenolic Acid 321.1 207.0 10 80 16

18


Results

Cyclosporin D Everolimus Mycophenolic Acid Gluc

TacrolimusCyclosporin A Mycophenolic Acid-D3

ts

Sirolimus Mycophenolic AcidAscomycin

Cou

nt

(MPA-G*)

Retention Time (min)Retention Time (min)

19

Due to the presence of mycophenolic acid glucuronide (MPA-G) in plasma, chromatography is particularly important to the research analysis of mycophenolic acid. MPA-G is susceptible to in-source fragmentation where glucuronide is easily lost. If these analytes are not separated by retention time, deglucuronidated MPA-G (MP(MPAA-G*)G*) cancan falselyfalsely elevateelevate thethe determinationdetermination ofof mycophenolicmycophenolic acidacid concentrationsconcentrations.


ResultsCalibration curves for five immunosuppressive drugspp g

(a) Cyclosporine A - 11 Levels, 11 Levels Used, 33 Points, 33 Points Used

0.8

0.9

1 y = 4.697286E-004 * x + 5.341801E-004R^2 = 0.99909117

(b) Everolimus - 10 Levels, 10 Levels Used, 30 Points, 30 Points Used

1 2

1.4

1.6 y = 0.029937 * x + 0.002344R^2 = 0.99703671

(c) MPA - 9 Levels, 9 Levels Used, 27 Points, 27 Points Used1x10

0 91

1.1y = 0.440706 * x + 0.004458R^2 = 0.99926392

0.2

0.3

0.4

0.5

0.6

0.7

0.8

0 2

0.4

0.6

0.8

1

1.2

0.20.30.40.50.60.70.80.9

0 200 400 600 800 100012001400160018002000

0

0.1

(d) Sirolimus - 10 Levels, 10 Levels Used, 30 Points, 30 Points Used

22.2

y = 0.042987 * x + 0.001519R^2 = 0.99763769

0 5 10 15 20 25 30 35 40 45 50

0

0.2

(e) Tacrolimus - 10 Levels, 10 Levels Used, 30 Points, 30 Points Used

6

7y = 0.141150 * x + 0.008016R^2 = 0.99803633

0 2 4 6 8 10 12 14 16 18 20 22 24 26

00.10.2

0 40.60.8

11.21.41.61.8

2

3

4

5

6

All curves show excellent linearity (R2 > 0.999). Curves are weighted 1/x. Accuracy within ±10% is retained

0 5 10 15 20 25 30 35 40 45 50

00.20.4

0 5 10 15 20 25 30 35 40 45 50

0

1

20

All curves show excellent linearity (R 0.999). Curves are weighted 1/x. Accuracy within ±10% is retainedthroughout the entire range for each curve.


ResultsSummary of analyte performance for five immunosuppressi iive ddrugs for research

Compound R2 Level Concentration(ng/ml)

Accuracy (%)n = 3

Intraday CV (%)n = 3

Interday CV (%)n = 6( g )

Cyclosporin A 0.999LLOQ 3.9 91.8 13.1 13.1MID 250.0 99.9 2.0 2.7ULOQ 2000.0 101.6 1.8 1.9

E li 0 999LLOQ 0.4 106.2 19.0 19.5

Everolimus 0.999 MID 12.5 105.9 2.8 4.4ULOQ 50.0 96.5 1.3 1.7

Mycophenolic Acid* 0.999

LLOQ 0.1 100.0 0.3 7.5MID 3.1 100.6 0.7 0.6ULOQ 25 0 101 7 0 6 0 7ULOQ 25.0 101.7 0.6 0.7

Sirolimus 0.999LLOQ 0.4 98.2 1.4 4.6MID 12.5 104.7 2.6 4.0ULOQ 50.0 98.0 2.6 1.9LLOQ 0.2 94.2 10.9 11.6

*MPA concentrations are in µg/ml concentrationsN Si l i i d CV i di h LLOQ l h d h f l l

Tacrolimus 0.999 MID 12.5 104.7 0.8 3.0ULOQ 50.0 96.8 2.0 2.0

21

Note: Signal to noise ratios and CVs indicate that LLOQs are lower than measured here for several analytes.


Two minute research method for quantifying four immunosuppressive drugs Cyclosporin A, everolilimus, siroi lliimus andd tacrot lliimus

22


Two minute research method for quantifying four immunosuppressive drugs Cyclosporin A, everolimus, sirolimussirolimus andand tacrolimustacrolimus

• Same sample preparation (whole blood only)

• Same LC configuration for on-line sample cleanup

• Modified LC conditions since MPA/MPA-G separation is notrequired

• Same MS/MS parameters

• Modified MRM transitions table

23


Two minute research method LC Conditions


Columns Temp: 60 °C Injection volume: 40 µL Needle Wash: 1:1:1:1 MeOH:ACN:IPA:H2O + 0.1% formic acid

10 secondsInjector Temp: 4 °C S it hi V l 0 0 i t P iti 1Switching Valve: 0.0 minutes – Position 1


Mobile Phase: A: 10 mM NH4 Acetate + 0.2% Formic Acid in WaterB: 10 mM NH4 Acetate + 0 2% Formic Acid in Methanol

Time Flow % Solvent A0.00 0.1 50

Time Flow % Solvent B0.00 0.5 95

B: 10 mM NH4 Acetate + 0.2% Formic Acid in Methanol


0.01 2.5 501.50 2.5 501.80 0.1 502.00 0.1 50

1.30 0.5 951.35 1.0 951.55 1.0 951.65 0.5 952.00 0.5 95

24


Two minute research method LC Conditions


Columns Temp: 60 °C Injection volume: 40 µL Needle Wash: 1:1:1:1 MeOH:ACN:IPA:H2O + 0.1% formic acid

10 secondsInjector Temp: 4 °C S it hi V l 0 0 i t P iti 1Switching Valve: 0.0 minutes – Position 1


Mobile Phase: A: 10 mM NH4 Acetate + 0.2% Formic Acid in WaterB: 10 mM NH4 Acetate + 0 2% Formic Acid in Methanol

Time Flow % Solvent A0.00 0.1 50

Time Flow % Solvent B0.00 0.5 95

B: 10 mM NH4 Acetate + 0.2% Formic Acid in Methanol


0.01 2.5 501.50 2.5 501.80 0.1 502.00 0.1 50

1.30 0.5 951.35 1.0 951.55 1.0 951.65 0.5 952.00 0.5 95

25


Internal Standards

Analyte Internal StandardCyclosporin A Cyclosporin DEverolimus AscomycinSirolimus AscomycinTacrolimus Ascomyciny

26


MRM Transitions tableAll precursor ions are ammonium adducts p

Compound Prec Ion Prod Ion Dwell Frag (V) CE (V)Cyclosporine D 1233.9 1216.9 10 175 12Cyclosporine A 1219.9 1202.8 10 170 12Everolimus 975.6 908.5 10 185 12Sirolimus 931.6 864.5 10 170 12Tacrolimus 821.5 768.4 10 170 16Ascomycin 809.5 756.4 10 175 16

27


Results

Cyclosporin A Sirolimus

Everolimus Tacrolimus

28


Results

Whole blood blank extracts Lowest concentrations injected

Cyclosporin A 1.95 ng/mL

Everolimus 0.1 ng/mL

Sirolimus 0.1 ng/mL

Tacrolimus 0.1 ng/mL

November 14, 2011Confidentiality Label

29


ResultsCalibration curves for four immunosuppppressive druggs for research

30


ResultsSummary of analyte performance for research for four immunosuppressive drugs

Concentration Accuracy (%) Intraday CV (%) Interday CV (%)Compound R2 Level Concentration(ng/ml)

Accuracy (%)n = 3

Intraday CV (%)n = 3

Interday CV (%)n = 6

Cyclosporin A 0.9996LLOQ 1.95 112.8 3.9 3.9MID 250.0 98.7 2.4 1.7ULOQ 2000.0 100.0 1.1 1.3

Everolimus 0.9995LLOQ 0.1 111.0 10.7 9.2MID 12.5 101.6 1.0 1.8ULOQ 50.0 99.4 1.4 1.2

Sirolimus 0 9988LLOQ 0.1 98.3 7.5 6.8MID 12 5 103 1 2 8 2 0Sirolimus 0.9988 MID 12.5 103.1 2.8 2.0ULOQ 50.0 97.1 1.7 1.7

Tacrolimus 0.9998LLOQ 0.1 103.1 7.3 5.8MID 12.5 100.0 1.2 1.2ULOQ 50.0 99.9 1.4 1.2ULOQ 50.0 99.9 1.4 1.2

Note: Signal to noise ratios and CVs indicate that LLOQs are lower than measured here for several analytes.

31


Questions

32


Calibrators – Internal Standards – ControlsWhich one?

- Calibrators prepared in whole blood or plasma are needed tobuild a calibration curve covering the linear range ofquantitationquantitation

- Internal standards are necessary for MS/MS quantitation

Controls prepared in whole blood or plasma are needed to- Controls prepared in whole blood or plasma are needed toverify suitability of the analytical method

33



- Calibrators prepared in whole blood or plasma are needed tobuild a calibration curve covering the linear range ofquantitationquantitation

- Internal standards are necessary for MS/MS quantitation

Controls prepared in whole blood or plasma are needed to- Controls prepared in whole blood or plasma are needed toverify suitability of the analytical method

However there are multiple choices available andHowever, there are multiple choices available and a decision on which one to use has to be made based on price and on regional availabilityp g y

34



Company CalibratorsIn whole

blood

Reference materials

Internalstandards

Controls

SAnalytical Services International LTD x x

Biorad x

Chromsystems x x x

Cerilliant x xCerilliant x x

Enzo Life Sciences X

Medical Isotopes X

Recipe x x xRecipe x x x

Santa Cruz Biotechnologies x

Sigma-Aldrich x x

Toronto Research Chemicals xo o o esea c C e ca s

Utak x

Home made x x

Others?

35


Calibrators, Internal Standards, ControlsChoices for this projectp j

ResearchMethod

Calibrators Internal Standards Controls

Four minute method

- Home made in whole blood withCerilliant (cyclosporin A,

- Cerilliant for MPA-d3- Sigma for ascomycin

NAmethod ( y p ,

sirolimus and tacrolimus) andSigma (everolimus) referencestandards

- Home made in plasma with

g y- Santa Cruz

Biotechnologies forcyclosporine D

pCerilliant (MPA and MPA-Gluc)reference standards

36


Calibrators, Internal Standards, ControlsChoices for this projectp j

Method Calibrators Internal Standards Controls

Four minute method

- Home made in whole blood withCerilliant (cyclosporin A,

- Cerilliant for MPA-d3- Sigma for ascomycin

NAmethod ( y p ,


- Home made in plasma with

g y- Santa Cruz

Biotechnologies forcyclosporine D

pCerilliant (MPA and MPA-Gluc)reference standards

Two minute th d

- Home made in whole blood withCerilliant (cyclosporin A

- Sigma for ascomycinSanta Cruz

Collaboratormethod Cerilliant (cyclosporin A,


- Santa Cruz Biotechnologies for cyclosporine D

37


Collaborator results for controls for the TwTwoo minuteminute research methodmethod

Compound Target (ng/mL) Mean (ng/mL)n=45

% of Target CV (%)n=45

Cyclosporine A95.6 95.6 100.0 6.3

187.0 197.6 105.6 4.9307.0 321.6 104.8 4.8

Sirolimus5.1 4.8 93.6 13.98.5 8.6 100.9 11.5

17.3 17.9 103.4 10.44 2 4 5 108 1 7 4

Tacrolimus4.2 4.5 108.1 7.47.6 7.7 101.3 6.6

12.5 13.1 104.9 7.9

Notes:Notes:Data acquired over 14 days by 4 different operators (45 measurements)Reference calibrators: ChromSystemsControls: BioradInternal Standards: ascomycin (Enzo Life Sciences), sirolimus-d3 (Medical isotopes),

38

cyclosporine A-d4 (Toronto Research Chemicals)


Tips and tricks

• Sodium adducts vs ammonium adducts

• Washes at the end of a batch

• Vial size and pre-slit septa

• Mobile phase quality (grade and freshness)

• Inline filter between needle seat and injection valve

• Pipetting technique: manual vs electronic pipettesPipetting technique: manual vs electronic pipettes

39


Supplies

SSupplier: Part number: Description:Agilent 821125-936 Trapping Column: Zorbax Eclipse Plus C18,

2.1x12.5mm, 5 µMAgilent 820888-901 Guard column hardware kit for trapping

columnAgilent 699975-302 Analytical column: Poroshell 120 EC-C18,

3 50 2 7 M3x50mm, 2.7 µMAgilent 5183-4511 Pre-slit septaVWR 97047-518 500 µL polypropylene micro vialsAgilent 5067-1551 Inline filter 2 mm, 0.2 µm

40


Review and Summary

• Successful four research minute method for quantifying five immunosuppressive drugs Cyclosporin A, everolimus, mycophenolic acid, sirolimus and tacrolimus

• High throughput two research minute method for quantifying four immunosuppressiveimmunosuppressive drugsdrugs CyclosporinCyclosporin AA, everolimuseverolimus, sirolimussirolimus andand tacrolimus

• Back-flushing, matrix-stripping liquid chromatography to reduce the throughput of matrix to the mass spectrometer

• UU ising ththe same hharddware andd reagentts ffor bbothth research meththodds allllowiing ffor ththe greatest flexibility while eliminating the need to maintain multiple configurations and solvents

• Typypical pperformance results for both methods are well within accepptance criteria

• Choices for Calibrators, Internal Standards and Controls

41


Acknowledgements

• Kevin McCann• LC/MS Application Champion, Agilent Technologies, Santa Clara, California, USA

• Andre Szczesniewski• LC/MS Application Specialist, Agilent Technologies, Schaumburg, Illinois, USA

• Peter Christensen• LC/MS Application Specialist, Agilent Technologies, Cheadle, UK

• DennisDennis--AlbertAlbert NagtalonNagtalon• Program marketing manager, Agilent Technologies, Santa Clara, California, USA

42


Questions and Answers

Linda CôtéLCMS Application Specialist

AAgili enl tt TTechhnologl iiesMontréal, Québec

Canada

Phone : 514-832-2854 [email protected]

43


Documents

Rapid Quantitative Analysis of nalysis of